谷草转氨酶与代谢综合征的相关性研究

Abstract
Figure/Table
References (23)
Related Citation (15)

Download: PDF (689 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the association of aspartate transaminase (AST) with metabolic syndrome (MS) and its components, in order to provide scientific basis for the early diagnosis of MS. Methods Individuals taken continuous physical examination in Physical Examination Center of Beijing Xiaotangshan Hospital from January 2012 to December 2015 were recruited in the study. Pearson correlation was used to analyze the correlation of baseline AST with MS and its components. The subjects were divided into four groups according to the baseline AST quartile (AST 1-4, from AST lowest to highest). Generalized estimation equation was applied for data analysis. Results There were 2003 males, average of (45.52±14.33) years old; and 2050 females, average age of (42.39±11.72) years old. The incidence of MS was 0.94% in the four years. The average baseline (2012 year) AST level [(19.24±0.12) U/L] was significantly lower than individuals in 2015 [(20.99±0.15) U/L], with statistically significant difference (P ＜ 0.05). Pearson analysis and adjustment of age and other components of MS showed that there were positive correlations between AST and FPG, TG (P < 0.01). Generalized estimation equation revealed that increased AST was positively correlated to the higher risk of MS after age and sex being adjusted (OR=1.00793, 95%CI:1.00351-1.01236, P=0.00043). Conclusion AST is closely correlated with MS and its components, and it can be used as a predictor of MS.

Key words： Aspartate aminotransferase Metabolic syndrome Obesity Blood pressure Lipids

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Dan JIA Zhongping BAI Xueqin LI Liyun XU Junfeng

Cite this article:

HUANG Dan JIA Zhongping BAI Xueqin LI Liyun XU Junfeng. Association between aspartate aminotransferase and metabolic syndrome[J]. 中国医药导报, 2017, 14(23): 114-117.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I23/114

[1] Alberti K，Eckel RH，Grundy SM，et al. Harmonizing the metabolic syndrome. A joint interim statement of the IDF Task Force on Epidemiology and Prevention；NHL and Blood Institute；AHA；WHF；IAS；and IA for the Study of Obesity [J]. Circulation，2009，120（16）：1640-1645.
[2] Reaven GM. The metabolic syndrome： is this diagnosis necessary?[J]. Am J Clin Nutr，2006，83（6）：1237-1247.
[3] Dehghan A，Van Hoek M，Sijbrands EJG，et al. High serum uric acid as a novel risk factor for type 2 diabetes [J]. Diabetes Care，2008，31（2）：361-362.
[4] Ross R. Atherosclerosis——an inflammatory disease [J]. New Engl J Med，1999，340（2）：115-126.
[5] Hulthe J，Bokemark L，Wikstrand J，et al. The metabolic syndrome，LDL particle size，and atherosclerosis [J]. Arter Thromb Vasc Biol， 2000， 20（9）：2140-2147.
[6] Ryu S，Song J，Choi BY，et al. Incidence and risk factors for metabolic syndrome in Korean male workers，ages 30 to 39 [J]. Ann Epidemiol，2007，17（4）：245-252.
[7] Liu X，Hamnvik OPR，Chamberland JP，et al. Circulating alanine transaminase（ALT）and γ-glutamyl transferase（GGT），but not fetuin-A，are associated with metabolic risk factors，at baseline and at two-year follow-up：the prospective Cyprus Metabolism Study [J]. Metabolism，2014，63（6）：773-782.
[8] Chen C，Lu FC. The guidelines for prevention and control of overweight and obesity in Chinese adults [J]. BES，2003， 17：1-36.
[9] Scorletti E，Calder PC，Byrne CD. Non-alcoholic fatty liver disease and cardiovascular risk：metabolic aspects and novel treatments [J]. Endocrine，2011，40（3）：332-343.
[10] Targher G，Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease [J]. Atherosclerosis，2007，191（2）：235-240.
[11] Kwon YM，Oh SW，Hwang S，et al. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults [J]. Am J Gastroenterol，2012，107（12）：1852-1858.
[12] Asrih M，Jornayvaz FR. Metabolic syndrome and nonalcoholic fatty liver disease： Is insulin resistance the link?[J]. Mol Cell Endocrinol，2015，418（Suppl）：55-65.
[13] Vanni E，Bugianesi E，Kotronen A，et al. From the metabolic syndrome to NAFLD or vice versa?[J]. Digest Liver Dis，2010，42（5）：320-330.
[14] Byrne CD. Fatty liver：role of inflammation and fatty acid nutrition [J]. Prostaglandins Leukot Essen Fatty Acids，2010，82（4）：265-271.
[15] Targher G，Bertolini L，Rodella S，et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients [J]. Diabetes Care，2007，30（8）：2119-2121.
[16] Musso G，Gambino R，Durazzo M，et al. Adipokines in NASH：postprandial lipid metabolism as a link between adiponectin and liver disease [J]. Hepatology，2005，42（5）：1175-1183.
[17] Mohammadi F，Qorbani M，Kelishadi R，et al. Association of cardiometabolic risk factors and hepatic enzymes in a national sample of Iranian children and adolescents： the CASPIAN-III study [J]. J Pediatr Gastroenterol Nutr，2014，58（4）：463-468.
[18] Villegas R，Xiang YB，Elasy T，et al. Liver enzymes，type 2 diabetes，and metabolic syndrome in middle-aged，urban Chinese men [J]. Metab Syndr Relat Disord，2011， 9（4）：305-311.
[19] Elizondo-Montemayor L，Ugalde-Casas PA，Lam-Franco L，et al. Association of ALT and the metabolic syndrome among Mexican children [J]. Obes Res Clin Pract，2014， 8（1）：e79-e87.
[20] 蔡杰.正压通气治疗睡眠呼吸暂停综合征并代谢综合征临床应用价值[J].中国医药科学，2016，6（21）：179-181.DOI：10.3969/j.issn.2095-0616.2016.21.051.
[21] Lee K，Yang JH. Which liver enzymes are better indicators of metabolic syndrome in adolescents：the Fifth Korea National Health and Nutrition Examination Survey，2010 [J]. Metab Syndr Relat Disord，2013，11（4）：229-235.
[22] 黄绍鹏，周全，张婵，等.不同性别个体体脂肪率与代谢综合征的关系[J].中国医药科学，2015，5（14）：168-170.
[23] Liu X，Hamnvik OPR，Chamberland JP，et al. Circulating alanine transaminase（ALT）and γ-glutamyl transferase（GGT），but not fetuin-A，are associated with metabolic risk factors，at baseline and at two-year follow-up： the prospective Cyprus Metabolism Study [J]. Metabolism，2014，63（6）：773-782.